Enamel matrix derivative (EMD; Emdogain) vs placebo or control
Tooth loss · Patients affected by chronic, aggressive, or early onset periodontitis, with intrabony defects having an intrabony component of at least 3…
1 finding from 1 review
- Enamel matrix derivative (Emdogain®) for periodontal tissue regeneration in intrabony defects 2009 · Cochrane All outcomes1 year (time-points 1, 5 and 10 years planned)SoF (Emdogain vs Control): Tooth loss - See comment / See comment; too few teeth lost to undertake analysis. 371 participants (9 studies). No GRADE rating given.9 studies · 371 participantsGRADE not reported